Hassan Ashktorab

Prof. Hassan Ashktorab

Howard University
orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 April 2019 in Nutrients
Verified
Journal Article
Open access
PDF file
Hassan AshktorabHassan Ashktorab
Hassan Ashktorab
ASAkbar Soleimani
Akbar Soleimani
GSGulshan Singh
Gulshan Singh
AAAmr Amin
Amr Amin
Solmaz TabtabaeiSolmaz Tabtabaei
Solmaz Tabtabaei
Hassan BrimHassan Brim
Hassan Brim
Saffron is a natural compound that has been used for centuries in many parts of the world as a food colorant and additive. It was shown to have the ability to mitigate various disorders through its known anti-inflammatory and anti-oxidant properties. Several studies have shown the effectiveness of saffron in the treatment of various chronic diseases like inflammatory bowel diseases, Alzheimer’s, rheumatoid arthritis as well as common malignancies of the colon, stomach, lung, breast, and skin. Modern day drugs generally have unwanted side effects, which led to the current trend to use naturally occurring products with therapeutic properties. In the present review, the objective is to systematically analyze the wealth of information regarding the potential mechanisms of action and the medical use of saffron, the “golden spice”, especially in digestive diseases. We summarized saffron influence on microbiome, molecular pathways, and inflammation in gastric, colon, liver cancers, and associated inflammations.

11 September 2009 in PLOS ONE
Verified
Journal Article
Open access
PDF file
PMpooneh mokarram
pooneh mokarram
KKKrishan Kumar
Krishan Kumar
HBHassan Brim
Hassan Brim
FNFakhraddin Naghibalhossaini
Fakhraddin Naghibalhossaini
MSMehdi Saberi-Firoozi
Mehdi Saberi-Firoozi
Hassan AshktorabHassan Ashktorab
Hassan Ashktorab
Mutations and promoters' methylation of a set of candidate cancer genes (CAN genes) are associated with progression of colorectal cancer (CRC). We hypothesized that these genes' promoters are inactivated through epigenetic silencing and may show a different profile in high-risk populations. We investigated the status of CAN gene methylation and CHD5 protein expression in African American CRC tissue microarrays (TMA) using immunohistochemical staining. The promoter methylation status of the CAN genes was studied by methylation-specific PCR (MSP) in 51 Iranians (a white population) and 51 African Americans (AA). Microsatellite instability (MSI) was analyzed as well. The differential frequency of methylation for each gene was tested by chi-square analysis between the two groups based on matched age and sex. CHD5 protein expression was evaluated in moderate to well differentiated and poorly differentiated carcinomas compared to matched normal tissue using TMA. In addition, the correlation between these epigenetic biomarkers and various clinicopathological factors, including, age, location, and stage of the disease were analyzed. Seventy-seven and 34% of tumors were distal in Iranian and African American patients, respectively. In both populations, the percentage of methylation was >65% for SYNE1, MMP2, APC2, GPNMB, EVL, PTPRD, and STARD8, whereas methylation was <50% for LGR6, RET, CD109, and RNF. The difference in methylation between the two populations was statistically significant for CHD5, ICAM5 and GPNMB. Thirty-one percent AA tumors showed MSI-H, compared to 28% in Iranians. A significantly higher methylation rate was found for GPNMB, ICAM5, and CHD5 genes in AA patients compared to Iranians. These genes might play a role in the high incidence and aggressiveness of CRC in the AA population. The hypermethylation of the CAN genes can be considered as a marker of colon carcinogenesis.

5 December 2008 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
Hassan AshktorabHassan Ashktorab
Hassan Ashktorab
KBKevin Belgrave
Kevin Belgrave
FHFatemeh Hosseinkhah
Fatemeh Hosseinkhah
HBHassan Brim
Hassan Brim
MNMehdi Nouraie
Mehdi Nouraie
DSDuane Smoot
Duane Smoot

26 January 2010 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Hassan AshktorabHassan Ashktorab
Hassan Ashktorab
ASAlejandro A. Schäffer
Alejandro A. Schäffer
MDMohammad Daremipouran
Mohammad Daremipouran
DSDuane T. Smoot
Duane T. Smoot
ELEdward Lee
Edward Lee
HBHassan Brim
Hassan Brim
Colon cancer (CRC) development often includes chromosomal instability (CIN) leading to amplifications and deletions of large DNA segments. Epidemiological, clinical, and cytogenetic studies showed that there are considerable differences between CRC tumors from African Americans (AAs) and Caucasian patients. In this study, we determined genomic copy number aberrations in sporadic CRC tumors from AAs, in order to investigate possible explanations for the observed disparities. We applied genome-wide array comparative genome hybridization (aCGH) using a 105k chip to identify copy number aberrations in samples from 15 AAs. In addition, we did a population comparative analysis with aCGH data in Caucasians as well as with a widely publicized list of colon cancer genes (CAN genes). There was an average of 20 aberrations per patient with more amplifications than deletions. Analysis of DNA copy number of frequently altered chromosomes revealed that deletions occurred primarily in chromosomes 4, 8 and 18. Chromosomal duplications occurred in more than 50% of cases on chromosomes 7, 8, 13, 20 and X. The CIN profile showed some differences when compared to Caucasian alterations. Chromosome X amplification in male patients and chromosomes 4, 8 and 18 deletions were prominent aberrations in AAs. Some CAN genes were altered at high frequencies in AAs with EXOC4, EPHB6, GNAS, MLL3 and TBX22 as the most frequently deleted genes and HAPLN1, ADAM29, SMAD2 and SMAD4 as the most frequently amplified genes. The observed CIN may play a distinctive role in CRC in AAs.

23 April 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
Hassan AshktorabHassan Ashktorab
Hassan Ashktorab
SASadhna Ahuja
Sadhna Ahuja
LKLakshmi Kannan
Lakshmi Kannan
XLXavier Llor
Xavier Llor
NENathan A. Ellis
Nathan A. Ellis
MNMehdi Nouraie
Mehdi Nouraie
A meta-analysis of MSI frequency and race in colorectal cancer

24 June 2021 in Molecules
Verified
Journal Article
Open access
PDF file
AAAmr Amin
Amr Amin
AFAaminah Farrukh
Aaminah Farrukh
CMChandraprabha Murali
Chandraprabha Murali
ASAkbar Soleimani
Akbar Soleimani
FPFrançoise PRAZ
Françoise PRAZ
Hassan AshktorabHassan Ashktorab
Hassan Ashktorab
Background: Colorectal cancer (CRC) is one of the most common cancers worldwide. One of its subtypes is associated with defective mismatch repair (dMMR) genes. Saffron has many potentially protective roles against colon malignancy. However, these roles in the context of dMMR tumors have not been explored. In this study, we aimed to investigate the effects of saffron and its constituents in CRC cell lines with dMMR. Methods: Saffron crude extracts and specific compounds (safranal and crocin) were used in the human colorectal cancer cell lines HCT116, HCT116+3 (inserted MLH1), HCT116+5 (inserted MSH3), and HCT116+3+5 (inserted MLH1 and MSH3). CDC25b, p-H2AX, TPDP1, and GAPDH were analyzed by Western blot. Proliferation and cytotoxicity were analyzed by MTT. The scratch wound assay was also performed. Results: Saffron crude extracts restricted (up to 70%) the proliferation in colon cells with deficient MMR (HCT116) compared to proficient MMR. The wound healing assay indicates that deficient MMR cells are doing better (up to 90%) than proficient MMR cells when treated with saffron. CDC25b and TDP1 downregulated (up to 20-fold) in proficient MMR cells compared to deficient MMR cells, while p.H2AX was significantly upregulated in both cell types, particularly at >10 mg/mL saffron in a concentration-dependent manner. The reduction in cellular proliferation was accompanied with upregulation of caspase 3 and 7. The major active saffron compounds, safranal and crocin reproduced most of the saffron crude extracts’ effects. Conclusions: Saffron’s anti-proliferative effect is significant in cells with deficient MMR. This novel effect may have therapeutic implications and benefits for MSI CRC patients who are generally not recommended for the 5-fluorouracil-based treatment.